The Scalar Formula
The Scalar Formula: why results multiply, and why one zero sinks them all
People × Culture × Strategy × Communication × Adoption × Execution = Results. Why the signs matter, and how to strengthen each factor.
Insights
Practical thinking on launches, growth and deals.
Lessons from two decades in commercial leadership.
Insights · Perspectives
Perspectives
The Scalar Formula, launches and U.S. entry: how I approach growth.
Healthcare · Launch
The five decisions that make or break a U.S. launch
Most launches are decided long before launch day. These are the five calls that matter most, and when to make them.
Healthcare · U.S. entry
Entering the U.S. market: a playbook for overseas healthcare companies
The U.S. rewards companies that prepare for it as many markets, not one. A practical sequence for getting there.
Insights · Trends
Trends
The market shifts changing how life-science companies grow: trade and reshoring, and what investors look for in commercial diligence.
Trends · U.S. entry
Entering the U.S. in the age of tariffs and reshoring
Trade policy is reshaping how overseas companies come to America. What has changed, what hasn't, and how to build a U.S. entry plan that holds up.
Trends · Private equity
What PE investors miss in healthcare commercial due diligence
Healthcare private equity just had a record year. The financial model is rarely what goes wrong. Five commercial questions investors should test before they sign.
Insights · Pharma Trends
Pharma Trends
Patent cliffs, Medicare negotiation and global licensing: what they mean for BD, launches and lifecycle strategy.
Pharma Trends · BD & M&A
The patent cliff is here: how loss of exclusivity is driving pharma BD and M&A
Hundreds of billions in revenue will lose exclusivity this decade. How the cliff is reshaping business development, how to choose between build, buy and partner, and what smaller companies should do.
Pharma Trends · Access & pricing
Medicare drug price negotiation: what it means for launch and lifecycle strategy
Negotiated prices are now real, and the rules keep evolving. How the program changes the way companies plan launches, indications and evidence.
Pharma Trends · Licensing & launch
In-licensing from China and the rise of lean, partner-led U.S. launches
More of the global pipeline now originates outside the U.S., and more launches are led by first-time companies. What a lean, partner-led U.S. launch needs to succeed.
Pharma Trends · U.S. launch
U.S. launch options for ex-U.S. biotechs: partner, co-promote or build
The U.S. is usually the first and biggest market for a new medicine. How a biotech based outside the U.S. should choose between licensing, co-promotion and building its own launch.
Free one-page guide
Get the U.S. Market Entry Playbook
Ten steps and the pitfalls to avoid, for life-science companies bringing a medicine to the United States.
Download the PDF
Free, no sign-up. Privacy.
30-minute call with Emilio
Not sure which door is yours? Start with a 30-minute call.
Tell me where the business is and what has to happen next. No obligation, and if Scalar isn't the right fit, I'll say so.
I reply personally.